Pharmaron Shareholders Back Board Changes and Governance Policy Upgrades at 2025 EGM

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialAn update from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available. Pharmaron Beijing Co., Ltd. announced that it successfully held its first extraordinary general meeting of 2025 in Beijing, with shareholders representing approximately 48.6% of voting share capital participating either in person or by proxy. All proposed ordinary resolutions were passed by a large majority, including the by‑election of an independent non‑executive director for the third session of the board and a series of amendments to key corporate governance and risk‑management policies, covering related‑party and connected transactions, external guarantees, external investments, independent non‑executive directors’ working procedures, use of proceeds, cumulative voting rules, and director nomination procedures. The strong approval rates underscore broad shareholder support for the company’s governance framework, which may strengthen regulatory compliance, enhance oversight of capital use and transactions, and reinforce the board’s independence, with potential implications for investor confidence and the company’s long‑term governance standards. The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page. More about Pharmaron Beijing Co., Ltd. Class H Pharmaron Beijing Co., Ltd. is a China-based company listed in Hong Kong that operates in the pharmaceutical and life sciences sector, providing outsourced research, development, and manufacturing services to global biopharmaceutical customers. Through its A-share and H-share structure, the company serves both domestic and international capital markets, reflecting its focus on supporting drug discovery and development across major healthcare markets. Average Trading Volume: 5,297,525 Technical Sentiment Signal: Buy Current Market Cap: HK$51.92B Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.